Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface

Journal of Thoracic and Cardiovascular Surgery

Volumn 124, Issue 2, 2002, Pages 321-332

  Johnell, Matilda ^a   Elgue, Graciela ^a   Larsson, Rolf ^a   Larsson, Anders ^a   Thelin, Stefan ^a   Siegbahn, Agneta ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN;

ADULT; AGED; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOCOMPATIBILITY; BLOOD CLOTTING; CELL ACTIVATION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DEVICE; DOSE RESPONSE; FEMALE; FIBRINOLYSIS; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM; PERICARDIUM; PRIORITY JOURNAL;

EID: 0036672682     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1067/mtc.2002.122551     Document Type: Article

References (44)

1. Systemic inflammation present in patients undergoing CABG without extracorporeal circulation
2. Activation of coagulation and fibrinolysis during cardiothoracic operations
3. Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass
4. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass
5. Two-chain factor VIIa generated in the pericardium during surgery with cardiopulmonary bypass: Relationship to increased thrombin generation and heparin concentration
6. Role of factor XII in thrombin generation and fibrinolysis during cardiopulmonary bypass
7. Heparin coating of extracorporeal circuits inhibits contact activation during cardiac operations
8. High molecular weight kininogen deficiency: A patient who underwent cardiac surgery
9. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue
10. Coagulofibrinolysis during heparin-coated cardiopulmonary bypass with reduced heparinization
11. High and low heparin dose with heparin-coated cardiopulmonary bypass: Activation of complement and granulocytes
12. Effect of anticoagulation protocol on outcome in patients undergoing CABG with heparin-bonded cardiopulmonary bypass circuits
13. Autotransfusion of shed mediastinal blood after cardiac surgery: A prospective study
14. Shed mediastinal blood transfusion after cardiac operations: A cost-effectiveness analysis
15. Autotransfusion after coronary artery bypass grafting halves the number of patients needing blood transfusion
16. Retransfusion of thoracic wound blood during heart surgery obscures biocompatibility of the extracorporeal circuit
17. A prospective randomised controlled trial of postoperative autotransfusion with and without a heparin-bonded circuit
18. Thrombin generation during cardiopulmonary bypass using heparin-coated or standard circuits
19. Tissue-type plasminogen activator and fibrin monomers synergistically cause platelet dysfunction during retransfusion of shed blood after cardiopulmonary bypass
20. The inflammatory cytokine response after autotransfusion of shed mediastinal blood
21. Systemic blood activation during and after autotransfusion
22. Adverse effects of postoperative infusion of shed mediastinal blood
23. Heparincoated coronary stents
24. Studies of adsorption, activation, and inhibition of factor XII on immobilized heparin
25. Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass
26. Heparin-coated circuits reduce occult myocardial damage during CPB: A randomized, single blind clinical trial
27. Completely heparinized cardiopulmonary bypass and reduced systemic heparin: Clinical and hemostatic effects
28. Heparin-coating of extracorporeal circuits reduce thrombin formation in patients undergoing cardiopulmonary bypass
29. No benefit of reduced heparinization in thoracic aortic operation with heparin-coated bypass circuits
30. Cardiopulmonary bypass with heparin-coated circuits and reduced systemic anticoagulation
31. Heparinized cardiopulmonary bypass and full heparin dose marginally improve clinical performance
32. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI)
33. Physiological function of tissue factor pathway inhibitor and interaction with heparins
34. Heparin inhibits ligand binding to the leukocyte integrin Mac-1 (CD11b/CD18)
35. High-dose heparin decreases nitric oxide production by cultured bovine endothelial cells
36. On the control of the plasma contact activation system on human endothelium: Comparisons with hepafin surface
37. Factor XI activation in a revised model of blood coagulation
38. Aprotinin inhibits thrombin formation and monocyte tissue factor in simulated cardiopulmonary bypass
39. Autotransfusion after coronary artery bypass surgery: Is there any benefit?
40. Hemorrhage and the use of blood products after adult cardiac operations: Myths and realities
41. Autotransfusion in coronary artery bypass grafting: Disparity in laboratory tests and clinical performance
42. Retransfusion of suctioned blood during cardiopulmonary bypass impairs hemostasis
43. Linkage between inflammation and coagulation: An update on the molecular basis of the crosstalk
44. IL-10 inhibits LPS-induced human monocyte tissue factor expression in whole blood